Cargando…

LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma

BACKGROUND & AIMS: Gemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yin-Xin, Li, Chi Han, Li, Guolin, Feng, Huiyi, Xia, Tian, Wong, Chi Hin, Fung, Frederic Khe Cheong, Tong, Joanna Hung-Man, To, Ka-Fai, Chen, Rufu, Chen, Yangchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505810/
https://www.ncbi.nlm.nih.gov/pubmed/32615164
http://dx.doi.org/10.1016/j.jcmgh.2020.06.009
_version_ 1783584893315317760
author Zhu, Yin-Xin
Li, Chi Han
Li, Guolin
Feng, Huiyi
Xia, Tian
Wong, Chi Hin
Fung, Frederic Khe Cheong
Tong, Joanna Hung-Man
To, Ka-Fai
Chen, Rufu
Chen, Yangchao
author_facet Zhu, Yin-Xin
Li, Chi Han
Li, Guolin
Feng, Huiyi
Xia, Tian
Wong, Chi Hin
Fung, Frederic Khe Cheong
Tong, Joanna Hung-Man
To, Ka-Fai
Chen, Rufu
Chen, Yangchao
author_sort Zhu, Yin-Xin
collection PubMed
description BACKGROUND & AIMS: Gemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as novel biomarkers to predict the gemcitabine response and the therapeutic targets to attenuate chemoresistance in PDAC cells. METHODS: Genome-wide RNA interference screening was conducted to identify genes that regulated gemcitabine chemoresistance. A cell proliferation assay and a tumor formation assay were conducted to study the role of lethal giant larvae homolog 1 (LLGL1) in gemcitabine chemoresistance. Levels of LLGL1 and its regulating targets were measured by immunohistochemical staining in tumor tissues obtained from patients who received gemcitabine as a single therapeutic agent. A gene-expression microarray was conducted to identify the targets regulated by LLGL1. RESULTS: Silencing of LLGL1 markedly reduced the gemcitabine chemosensitivity in PDAC cells. Patients had significantly shorter survival (6 months) if they bore tumors expressing low LLGL1 level than tumors with high LLGL1 level (20 months) (hazard ratio, 0.1567; 95% CI, 0.05966–0.4117). Loss of LLGL1 promoted cytokine receptor oncostatin M receptor (OSMR) expression in PDAC cells that led to gemcitabine resistance, while knockdown of OSMR effectively rescued the chemoresistance phenotype. The LLGL1-OSMR regulatory pathway showed great clinical importance because low LLGL1 and high OSMR expressions were observed frequently in PDAC tissues. Silencing of LLGL1 induced phosphorylation of extracellular signal-regulated kinase 2 and specificity protein 1 (Sp1), promoted Sp1 (pThr453) binding at the OSMR promoter, and enhanced OSMR transcription. CONCLUSIONS: LLGL1 possessed a tumor-suppressor role as an inhibitor of chemoresistance by regulating OSMR–extracellular signal-regulated kinase 2/Sp1 signaling. The data sets generated and analyzed during the current study are available in the Gene Expression Omnibus repository (ID: GSE64681).
format Online
Article
Text
id pubmed-7505810
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75058102020-09-28 LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma Zhu, Yin-Xin Li, Chi Han Li, Guolin Feng, Huiyi Xia, Tian Wong, Chi Hin Fung, Frederic Khe Cheong Tong, Joanna Hung-Man To, Ka-Fai Chen, Rufu Chen, Yangchao Cell Mol Gastroenterol Hepatol Original Research BACKGROUND & AIMS: Gemcitabine resistance is rapidly acquired by pancreatic ductal adenocarcinoma (PDAC) patients. Novel approaches that predict the gemcitabine response of patients and enhance gemcitabine chemosensitivity are important to improve patient survival. We aimed to identify genes as novel biomarkers to predict the gemcitabine response and the therapeutic targets to attenuate chemoresistance in PDAC cells. METHODS: Genome-wide RNA interference screening was conducted to identify genes that regulated gemcitabine chemoresistance. A cell proliferation assay and a tumor formation assay were conducted to study the role of lethal giant larvae homolog 1 (LLGL1) in gemcitabine chemoresistance. Levels of LLGL1 and its regulating targets were measured by immunohistochemical staining in tumor tissues obtained from patients who received gemcitabine as a single therapeutic agent. A gene-expression microarray was conducted to identify the targets regulated by LLGL1. RESULTS: Silencing of LLGL1 markedly reduced the gemcitabine chemosensitivity in PDAC cells. Patients had significantly shorter survival (6 months) if they bore tumors expressing low LLGL1 level than tumors with high LLGL1 level (20 months) (hazard ratio, 0.1567; 95% CI, 0.05966–0.4117). Loss of LLGL1 promoted cytokine receptor oncostatin M receptor (OSMR) expression in PDAC cells that led to gemcitabine resistance, while knockdown of OSMR effectively rescued the chemoresistance phenotype. The LLGL1-OSMR regulatory pathway showed great clinical importance because low LLGL1 and high OSMR expressions were observed frequently in PDAC tissues. Silencing of LLGL1 induced phosphorylation of extracellular signal-regulated kinase 2 and specificity protein 1 (Sp1), promoted Sp1 (pThr453) binding at the OSMR promoter, and enhanced OSMR transcription. CONCLUSIONS: LLGL1 possessed a tumor-suppressor role as an inhibitor of chemoresistance by regulating OSMR–extracellular signal-regulated kinase 2/Sp1 signaling. The data sets generated and analyzed during the current study are available in the Gene Expression Omnibus repository (ID: GSE64681). Elsevier 2020-06-29 /pmc/articles/PMC7505810/ /pubmed/32615164 http://dx.doi.org/10.1016/j.jcmgh.2020.06.009 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Zhu, Yin-Xin
Li, Chi Han
Li, Guolin
Feng, Huiyi
Xia, Tian
Wong, Chi Hin
Fung, Frederic Khe Cheong
Tong, Joanna Hung-Man
To, Ka-Fai
Chen, Rufu
Chen, Yangchao
LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
title LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
title_full LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
title_fullStr LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
title_full_unstemmed LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
title_short LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
title_sort llgl1 regulates gemcitabine resistance by modulating the erk-sp1-osmr pathway in pancreatic ductal adenocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505810/
https://www.ncbi.nlm.nih.gov/pubmed/32615164
http://dx.doi.org/10.1016/j.jcmgh.2020.06.009
work_keys_str_mv AT zhuyinxin llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT lichihan llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT liguolin llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT fenghuiyi llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT xiatian llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT wongchihin llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT fungfrederickhecheong llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT tongjoannahungman llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT tokafai llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT chenrufu llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma
AT chenyangchao llgl1regulatesgemcitabineresistancebymodulatingtheerksp1osmrpathwayinpancreaticductaladenocarcinoma